ロード中...
Immune checkpoint inhibitors for hepatocellular carcinoma
Hepatocellular carcinoma (HCC) is a leading cause of cancer deaths worldwide, and advanced HCC generally caries a poor prognosis. The treatment of advanced disease is limited to sorafenib, which provides only a limited improvement in survival, and novel therapies are, thus, sorely needed. Among emer...
保存先:
| 出版年: | Hepat Oncol |
|---|---|
| 主要な著者: | , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Future Medicine Ltd
2016
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6095178/ https://ncbi.nlm.nih.gov/pubmed/30191042 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/hep-2016-0004 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|